Archives

Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference by

Catherine Demers Recombinent human growth hormone has achieved clinical responses when used for treating heart failure. Catherine Demers of McMaster University told the American Heart Association conf

Anthony Keech Among nearly 10 000 patients with maturity onset diabetes the use of fenofibrate to lower cholesterol produced a 24 per cent statistically significant reduction of cardiovascular events,

Judith Hochman from New York University told Audio Medica that patients taking aspirin need to take it half an hour before any NSAID in order to avoid drug interactions, and had these comments about t

Gunnar Gislason As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other no

Frans van der Werf Near-complete data from the ASSENT-4-PCI trial investigating facilitated PCI (combining both thrombolysis and primary PCI after acute myocardial infarction) has found that PCI alone

Olivier Bertrand The use of abciximab perfusion after stenting was questioned at the American Heart Association meeting in Dallas. The EASY study found bolus administration of glycoprotein 2B3A inhibi

Milton Packer In the REVIVE trial the inotropic agent levosimendan has improved short-term outcome in acutely decompensated heart failure. Milton Packer from the University of Texas. [audio:https://ww

Gordon Tomaselli Gordon Tomaselli commented on Milton Packer’s findings at the Dallas meeting of the American Heart Association. [audio:https://www.audiomedica.com/podcasting/aha2005/Gordon_Toma

Bryan Williams Bryan Williams, University of Leicester Measuring blood pressure with a cuff around the arm does not always give a clear picture of what’s happening in the aorta. The CAFE study f

Volker Schächinger Regeneration of the heart has been achieved by using bone-marrow derived stem cells after myocardial infarction among 200 patients. Volker Schächinger, University of Frankfurt. [a

Gordon Tomaselli Gordon Tomaselli, Johns Hopkins School of Medicine Gordon Tomaselli commented on Volker Schächinger’s findings at the Dallas meeting of the American Heart Association. [audio:h

Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding

Andrew J Molyneux, Neurovascular Research Unit, Radcliffe Infirmary, Oxford REFERENCE: Lancet 2005;366:809-17 A trans-catheter treatment for ruptured intracranial aneurysm has proved superior to tradi

Keith Fox Keith Fox, Royal Infirmary Edinburgh The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress

Bruno Scheller Bruno Scheller, Universitatsklinikum des Saarlandes, Homburg Saar A future option for treating in-stent restenosis is the idea of coating a balloon with an anti-proliferative drug and i

Jean Fajadet The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse told Audio Medica about the findings from ENDEAVOR II study of arou

David Wood Heart disease patients need to change lifestyle and not just take medicines. That’s the message in Stockholm from the EuroAction Project, which is investigating the potential of a nur

Caroline Daly The Euroheart survey has found significant differences in both diagnosis and treatment of heart disease in women as compared with men. Audio Medica asked Caroline Daly of London’s

Audio Medica talked with Roberto Ferrari , Vice President of the ESC, about the PREAMI study on the use of the ACE inhibitor perindopril in older patients who have survived acute myocardial infarction

Frans Van de Werf In the treatment of acute myocardial infarction the 24-country ASSENT-4 study seems to show an overall increase of risk if you use thrombolysis before primary PCI. Frans Van de Werf

John Cleland Cardiac resynchronisation has proved even more beneficial in severe heart failure than was proven a year ago by early results from the CARE-HF study. At the European Cardiology meeting in

Ronnie Willenheimer It could be just as good to start treatment for heart failure with a beta blocker first and subsequently use an ACE inhibitor, as the more convetional use of an ACE inhibitor first

Gilles Montalescot The STEEPLE trial randomised more than 3500 elective angioplasty patients to unfractionated heparin or either of two dose levels of enoxaparin. Gilles Montalescot presented the find

Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pf